8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

SCHEDULE 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)

8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

DEFA14A - IQVIA HOLDINGS INC. (0001478242) (Filer)

DEF 14A - IQVIA HOLDINGS INC. (0001478242) (Filer)

PRE 14A - IQVIA HOLDINGS INC. (0001478242) (Filer)

HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00

Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00

BTIG Research downgraded IQVIA from Buy to Neutral

Stephens initiated coverage of IQVIA with a rating of Overweight and set a new price target of $250.00

Redburn Atlantic initiated coverage of IQVIA with a rating of Buy

RBC Capital Mkts initiated coverage of IQVIA with a rating of Outperform and set a new price target of $275.00

Jefferies downgraded IQVIA from Buy to Hold and set a new price target of $242.00 from $266.00 previously

Goldman initiated coverage of IQVIA with a rating of Buy and set a new price target of $270.00

Leerink Partners initiated coverage of IQVIA with a rating of Outperform and set a new price target of $290.00

Guggenheim downgraded IQVIA from Buy to Neutral

Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 17, 2025 /PRNewswire/ -- Venture Capital continues to flow in bunches into the AI in healthcare sector, with AI companies capturing more than half of digital health funding in Q1. Investors are seeking novel opportunities that tap into this space, with private companies such as Ellipsis Health and Autonomize AI recently receiving $45M and $28M respectively for their innovations. For other investors seeking opportunities among publicly traded companies, there's been plenty of development to follow from innovators, including from Avant Technologies, Inc. (OTCQB:AVAI), IQVIA Holdings Inc. (NYSE:IQV), S

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program. IQVIA's breakthrough Health Research Space platform allows direct-to-patient data collection and engagement with patient-facing mobile apps that helps patients and their caregivers participate in decentralized clinical trials around the world. The platform is configurable, multilingual and compatible with web, iOS and Android and is available across many geographic regions, increasing p

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA's new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI and deep domain expertise are transforming business processes and patient outcomes. "This is a pivotal opportunity to deliver the precise, efficient workflows and insights required by the modern life sciences industry backed by deep industry expertise and powerful technology partnersh

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2032 (the "Notes"). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The Notes will mature on June 1, 2032, unless earlier repurchased or redeemed in accordance with their terms. The Notes will bear interest at a rate of 6.250% per annum and will pay interest semi-annually in arrears on J

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the "Notes"). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solic

Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas, May 27, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development Innovations, this collaboration will enhance clinical trial processes, eliminate operational hurdles, accelerate data delivery and expedite the availability of cutting-edge therapies to patients. The collaboration leverages IQVIA's global reach

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Annual Health Care Conference on Tuesday, May 13, 2025, at 5:20 p.m. ET (2:20 p.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intellige

Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Marie E. Lamont, head of Real World Solutions (Patient Insights, Experience and Registry Solutions), and Dr. Joanne Hackett, vice president, Health System Services (Europe, Middle East, Africa and South Asia), have been honored by the Healthcare Businesswomen's Association (HBA). Marie has been named a Luminary, and Joanne has been recognized as a Rising Star. Marie was honored for her significant contributions to IQVIA including increasing the patient voice in research and care delivery combined wit

4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

IQVIA (NYSE:IQV) today announced the appointment of Sheila A. Stamps to its board of directors, effective today. Ms. Stamps brings more than four decades of strategic, governance and operational management experience. During her extensive career she held senior executive leadership positions in both public and private sector organizations, most recently as a senior investment advisor to the Comptroller of the State of New York for the NYS Common Retirement Fund and as Commissioner on the board of the New York State Insurance Fund, the state's largest provider of worker's compensation insurance. Prior to this, she was a Managing Director at Bank of America and Managing Director and Executive

IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, announced the appointment of Leslie Wims Morris to its board of directors, effective today. With more than 25 years of experience in financial services, Wims Morris is currently Managing Director and Head of Corporate Development for JPMorgan Chase's Consumer & Community Banking business, which serves more than 60 million households in the U.S. In this role, she leads the development and launch of strategic partnerships with leading technology, payments, e-commerce and fintech companies and participates in firmwide strategic initiatives. She is also

MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials related to the clinical development of ASLAN004 and ASLAN003. IQVIA Biotech will provide pati

BOSTON, Sept. 29, 2021 /PRNewswire-PRWeb/ -- Drumroll Health, a digital health company applying AI to simplify how organizations discover new insights from survey data, announced today the appointment of Pablo Graiver as new Chief Executive Officer of the company. Mr Graiver, visionary founder and former CEO of pioneering trial-matching company Antidote, brings an unparalleled wealth of experience and successful track record designing and scaling innovative technology solutions used every day by patients, researchers, and biopharma companies alike. "Drumroll Health is tapping into a very real and pressing need, making it easier and faster to translate survey data into clear, meaningful insig

Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency TAS Revenue of $1,658 million fo

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, part

Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported year-over-year TAS Revenue of $1,554 million, up 8.6 percent year-over-year Operating Cash Flow of $721 million, bringing year-to-date Operating Cash Flow to $1,831 million, up 31 percent year-over-year Free Cash Flow of $571 million, bringing year-to-date Free Ca

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will re

Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64 R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x R&D Solutions contracted backlog of $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year Full-year 2024 guidance updated for revenue to be between $15,425 million and $15,525 million, Adjusted EBITDA between $3,705 million and $3,765 million, and Adjusted Diluted Earnings per Share between $11.10 and $11.30 IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global pro

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will recei

Revenue of $3,737 million GAAP Net Income of $288 million, Adjusted EBITDA of $862 million GAAP Diluted Earnings per Share of $1.56, Adjusted Diluted Earnings per Share of $2.54 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.23x R&D Solutions contracted backlog of $30.1 billion, up 7.9 percent year-over-year IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2024. First-Quarter 2024 Operating Results Revenue for the first quarter of $3,737 millio

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2024 financial results before the market opens on Thursday, May 2, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receiv